Core Insights - Johnson Controls International plc (JCI) is valued at a market cap of $68 billion and specializes in HVAC equipment, building automation, fire detection, and security solutions for various sectors [1] Financial Performance - Analysts anticipate JCI to report a profit of $0.83 per share for fiscal Q1 2026, reflecting a 29.7% increase from $0.64 per share in the same quarter last year [2] - For fiscal 2026, JCI is expected to achieve a profit of $4.55 per share, which is a 21% increase from $3.76 per share in fiscal 2025, with further growth projected to $5.26 per share in fiscal 2027, representing a 15.6% year-over-year increase [3] Stock Performance - JCI's shares have increased by 39.2% over the past 52 weeks, significantly outperforming the S&P 500 Index's 17.5% return and the State Street Industrial Select Sector SPDR ETF's 21.7% increase during the same period [4] - Following the release of its Q4 earnings, JCI's shares surged by 8.8%, with total revenue rising 3.1% year-over-year to $6.4 billion, exceeding consensus estimates by 1.6% [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for JCI, with 12 out of 20 analysts recommending "Strong Buy" and 8 suggesting "Hold" [6] - The mean price target for JCI is set at $133.16, indicating a potential upside of 19.4% from current levels [6]

Core Insights - The Allstate Corporation (ALL) is set to announce its fiscal Q4 earnings for 2025 on February 4, with a current market cap of $54.2 billion [1] Financial Performance - Analysts anticipate a profit of $8.72 per share for Q4 2025, reflecting a 13.7% increase from $7.67 per share in the same quarter last year [2] - For the current fiscal year ending in December, expected profit is $28.81 per share, a significant 57.3% rise from $18.32 per share in fiscal 2024, although a decline of 17% to $23.91 per share is projected for fiscal 2026 [3] - In Q3, Allstate reported total revenue of $17.3 billion, a 3.8% year-over-year increase, and an adjusted EPS of $11.17, which is a remarkable 185.7% improvement from the previous year [5] Market Performance - Over the past 52 weeks, ALL's stock has gained 9.2%, underperforming the S&P 500 Index's 17.1% return and the State Street Financial Select Sector SPDR ETF's 15.6% increase [4] - Following the Q3 results announcement, ALL's shares surged by 1.7% in the subsequent trading session, indicating positive investor sentiment [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for ALL, with 13 out of 24 analysts recommending "Strong Buy," one suggesting "Moderate Buy," eight advising "Hold," and two indicating "Strong Sell" [6] - The mean price target for ALL is set at $240.64, suggesting a potential upside of 14.9% from current levels [6]

Core Insights - Boston Scientific Corporation (BSX) is a leading medical device company with a market cap of $140.4 billion, focusing on various interventional medical specialties globally [1] Financial Performance - Analysts expect BSX to report a profit of $0.78 per share for Q4 2025, reflecting an 11.4% increase from $0.70 per share in the same quarter last year [2] - For the full fiscal year 2025, BSX is projected to achieve an EPS of $3.04, which is a 21.1% increase from $2.51 in fiscal 2024 [3] - The EPS is anticipated to rise further to $3.45 in fiscal 2026, marking a year-over-year growth of 13.5% [3] Stock Performance - Over the past 52 weeks, BSX stock has increased by 7.2%, underperforming the S&P 500 Index, which gained 17.1%, and the Health Care Select Sector SPDR Fund, which returned 14.3% [4] - Following the Q3 results announcement on October 22, 2025, BSX shares rose by 4%, with an adjusted EPS of $0.75 exceeding Wall Street's expectation of $0.71 and revenue reaching $5.1 billion, surpassing forecasts of $5 billion [5] Analyst Ratings - The consensus opinion among analysts is bullish, with a "Strong Buy" rating for BSX stock; 26 out of 31 analysts recommend a "Strong Buy," while three suggest a "Moderate Buy" and two give a "Hold" [6] - The average analyst price target for BSX is $126.80, indicating a potential upside of 28.5% from current levels [6]

Core Viewpoint - Molina Healthcare, Inc. (MOH) is facing significant challenges with a projected decline in earnings, as indicated by analysts' forecasts for both the upcoming quarterly results and the full fiscal year 2025 [2][3]. Financial Performance - Molina Healthcare has a market capitalization of $9.7 billion and provides managed healthcare services primarily to low-income individuals and families through Medicaid, Medicare, and state insurance marketplace programs [1]. - For fiscal Q4 2025, analysts expect an adjusted EPS of $0.43, which represents a 91.5% decrease from $5.05 in the same quarter last year [2]. - The forecast for fiscal 2025 indicates an adjusted EPS of $13.95, down 38.4% from $22.65 in fiscal 2024 [3]. Stock Performance - Over the past 52 weeks, shares of Molina Healthcare have decreased by 38.1%, underperforming compared to the S&P 500 Index, which rose by 16.2%, and the State Street Health Care Select Sector SPDR ETF, which gained 13.7% [4]. - Following the Q3 2025 results announced on October 22, shares tumbled 17.5% as adjusted EPS fell to $1.84 from $6.01, primarily due to increased medical costs [5]. Analyst Ratings - The consensus rating for MOH stock is cautious, with a "Hold" rating overall. Among 18 analysts, three recommend a "Strong Buy," 12 suggest a "Hold," one indicates a "Moderate Sell," and two have a "Strong Sell" rating [6]. - Currently, the stock is trading above the average analyst price target of $167.67 [6].

Company Overview - Willis Towers Watson Public Limited Company (WTW) has a market cap of $31.2 billion and operates as a global advisory, broking, and solutions firm, helping organizations manage risk and improve employee benefits and investment outcomes [1] Earnings Expectations - WTW is expected to release its fiscal Q4 2025 earnings results soon, with analysts predicting an adjusted EPS of $7.93, a decrease of 2.5% from $8.13 in the same quarter last year [2] - For fiscal 2025, analysts forecast an adjusted EPS of $16.89, slightly down from $16.93 in fiscal 2024, but anticipate a 14% year-over-year growth to $19.26 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, WTW shares have increased by 8.3%, which is lower than the S&P 500 Index's gain of 16.2% and the Financial Select Sector SPDR Fund's return of 15.5% [4] Recent Developments - On December 15, WTW shares rose by 1.2% following the announcement of a $1 billion senior unsecured notes offering, which includes $700 million of 4.55% notes due in 2031 and $300 million of 5.15% notes due in 2036. The funding is intended to support the Newfront acquisition and refinance near-term debt, enhancing WTW's financial flexibility [5] Analyst Ratings - The consensus view among analysts on WTW stock is cautiously optimistic, with an overall "Moderate Buy" rating. Out of 24 analysts, 13 recommend "Strong Buy," one suggests "Moderate Buy," nine indicate "Hold," and one has a "Strong Sell." The average price target for WTW is $367.30, suggesting a potential upside of 9.8% from current levels [6]

Founded in 1930, Texas Instruments Incorporated (TXN) designs, manufactures, and sells semiconductors to electronics designers and manufacturers in the United States and internationally. The company is headquartered in Dallas, Texas and has a market capitalization of $161.3 billion. TXN is expected to release its Q4 fiscal 2025 earnings on Thursday, Jan. 22. Ahead of this event, analysts anticipate Texas Instruments to generate earnings of $1.28 per share, representing a decline of 1.5% from $1.30 per sh ...

Founded in 1892, Evendale, Ohio-based GE Aerospace (GE) designs and produces commercial and defense aircraft engines, integrated engine components, electric power, and mechanical aircraft systems. The company’s market cap is around $338.3 billion. The company is expected to announce its fiscal fourth-quarter earnings for 2025 on Thursday, Jan. 22. Ahead of the event, analysts expect GE Aerospace to report a profit of $1.40 per share on a diluted basis, up 6.1% from $1.32 per share in the year-ago quarter ...

Company Overview - LyondellBasell Industries N.V. is a major petrochemical and chemical company based in Houston, Texas, with a market cap of $14.3 billion. The company produces key chemical building blocks such as ethylene, propylene, polyethylene, and polypropylene, along with a variety of polymers, specialty chemicals, and fuels used in everyday applications like packaging, automotive components, construction materials, textiles, and consumer goods [1]. Financial Performance - Analysts expect LyondellBasell to report a non-GAAP profit of $0.19 per share for the fourth quarter, which represents a significant decline of 74.7% from $0.75 per share reported in the same quarter last year. The company has met or exceeded Street estimates on the bottom line twice in the past four quarters but has missed projections on two occasions [2]. - For fiscal 2025, analysts project a non-GAAP EPS of $2.22, down 65.3% from $6.40 in fiscal 2024. However, earnings are expected to rebound in fiscal 2026, with a projected increase of 61.7% year over year to $3.59 per share [3]. Stock Performance - LyondellBasell's stock has declined by 39% over the past 52 weeks, significantly underperforming the S&P 500 Index, which returned 16.9%, and the Materials Select Sector SPDR Fund, which saw a 10.9% decline during the same period [4]. - On December 15, LyondellBasell shares fell more than 2% following a downgrade by BMO Capital Markets, which changed its rating from "Market Perform" to "Underperform" and set a price target of $36. This downgrade was attributed to concerns over near-term headwinds in the chemicals and petrochemicals markets, including weaker global demand and margin pressure from rising feedstock costs [5]. Analyst Ratings - Analysts maintain a cautious outlook on LyondellBasell, with a consensus "Hold" rating. Among the 21 analysts covering the stock, there are two "Strong Buys," one "Moderate Buy," 14 "Holds," and four "Strong Sells." The mean price target of $50.70 indicates a potential upside of 14.2% from current price levels [6].

Core Viewpoint - Phillips 66 (PSX) is set to report its fiscal fourth-quarter earnings for 2025, with analysts anticipating a significant profit turnaround compared to the previous year [1][2]. Financial Performance - Analysts expect PSX to report a profit of $2.24 per share on a diluted basis, a notable increase from a loss of $0.15 per share in the same quarter last year [2]. - For the full year, PSX's EPS is projected to be $6.19, slightly up from $6.15 in fiscal 2024, with a forecasted rise to $12.23 in fiscal 2026, representing a year-over-year increase of 97.6% [3]. Stock Performance - Over the past 52 weeks, PSX shares have increased by 14.1%, underperforming the S&P 500 Index's gains of 16.9%, but outperforming the Energy Select Sector SPDR Fund's (XLE) gains of 5.4% [4]. - Following the Q3 results announcement, PSX shares closed up more than 3%, with an adjusted EPS of $2.52 exceeding Wall Street expectations of $2.07 [5]. Analyst Ratings - The consensus opinion on PSX stock is moderately bullish, with a "Moderate Buy" rating overall. Out of 20 analysts, nine recommend a "Strong Buy," one suggests a "Moderate Buy," and ten give a "Hold" rating [5]. - The average analyst price target for PSX is $148.65, indicating a potential upside of 13.8% from current levels [5].

Core Viewpoint - Cardinal Health, Inc. is poised to report strong fiscal second-quarter earnings for 2026, with significant growth in earnings per share (EPS) anticipated due to various strategic initiatives and market performance [1][2][5]. Financial Performance - Analysts expect Cardinal Health to report a profit of $2.31 per share on a diluted basis, reflecting a 19.7% increase from $1.93 per share in the same quarter last year [2]. - For the full fiscal year, EPS is projected to be $9.86, up 19.7% from $8.24 in fiscal 2025, with further growth expected to $10.90 in fiscal 2027, representing a year-over-year increase of 10.6% [3]. Stock Performance - Cardinal Health's stock has outperformed the S&P 500 Index, which gained 16.4% over the past 52 weeks, with CAH shares increasing by 74.3% during the same period [4]. - The company also significantly outperformed the Health Care Select Sector SPDR Fund, which returned 12.8% in the same timeframe [4]. Strategic Initiatives - The strong performance of Cardinal Health is attributed to the acquisition of Solaris Health, which added over 750 providers to its MSO platform, alongside robust organic growth in pharmaceuticals, generics, and specialty solutions [5]. - New customer acquisitions, effective cost controls, and investments in automation and logistics are enhancing profitability, with double-digit growth expected in specialty platforms such as autoimmune, urology, and oncology [5]. Recent Developments - On October 30, Cardinal Health shares rose more than 15% following the release of Q1 results, where adjusted EPS of $2.55 exceeded Wall Street expectations of $2.21, and revenue reached $64 billion, surpassing forecasts of $59.1 billion [6]. - The company anticipates full-year adjusted EPS to be in the range of $9.65 to $9.85 [6].